

RESEARCH ARTICLE

Open Access



Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma

Qin Tan¹, Chaoting Zhang^{2*}, Wenjun Yang³, Ying Liu¹, Palashati Heyilimu², Dongdong Feng⁴, Liying Xing², Yang Ke^{1*} and Zheming Lu^{2*}

Abstract

Background: T cell receptor-engineered T cells (TCR-Ts) therapy is a promising cancer treatment strategy. Nowadays, most studies focused on identification of high-avidity T cell receptors (TCRs) directed against neoantigens derived from somatic mutations. However, few neoantigens per patient could induce immune response in epithelial cancer and additionally many tumor-specific antigens could be derived from noncoding region. Autologous tumor cells (ATCs) could be unbiased stimulators in activating and enriching tumor-reactive T cells. However, it's unknown if T cells engineered to express TCRs isolated from tumor-reactive T cells enriched by ATCs have strong antitumor response.

Methods: In this study, multiple TIL fragments obtained from a patient with esophageal squamous cell carcinoma (ESCC) were screened for specific recognition of ATCs. Tumor-reactive TILs were enriched by in vitro repeated stimulation of ATCs and isolated based on CD137 upregulation. Subsequently, tumor-reactive TCR was obtained by single-cell RT-PCR analysis and was introduced into peripheral blood lymphocytes to generate TCR-Ts.

Results: We found that phenotype and effect function of TIL fragments derived from different tumor sites were spatially heterogeneous. Of four TIL fragments, only TIL-F1 could specifically identify ATCs. Subsequently, we isolated CD8⁺ CD137⁺ T cells from pre- and post-stimulated TIL-F1 co-cultured with ATCs, and identified their most dominant TCR. This TCR was introduced into PBLs to generate TCR-Ts, which specifically identified and killed ATCs in vivo and in vitro.

(Continued on next page)

* Correspondence: chaotingzhang@bjmu.edu.cn; keyang@bjmu.edu.cn; luzheming@bjmu.edu.cn

²Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Beijing 100142, China

¹Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Beijing 100142, China

Full list of author information is available at the end of the article



(Continued from previous page)

Conclusion: This strategy provides the means to generate tumor-reactive TCR-Ts for ESCC, which is especially important for patients without prior knowledge of specific epitopes and might be applied for other cancers.

Keywords: Tumor-infiltrating lymphocytes (TIL), T cell receptor-engineered T cells (TCR-Ts), Esophageal squamous cell cancer (ESCC), Autologous tumor cells, CD137

Background

Esophageal cancer is one of the most common cancers worldwide, with higher incidence rates in Eastern Asia and in Eastern and Southern Africa, in which esophageal squamous cell carcinoma (ESCC) is the predominant histologic type [1]. Despite advances in diagnosis and treatment, the prognosis of advanced ESCC remains poor, due to its invasive and diffuse nature [2]. Thus, new effective treatment strategies are urgently needed.

Adoptive cell therapy including T cell receptor-engineered T cells (TCR-Ts) has mediated effective anti-tumor responses in several cancers [3]. Tumor-specific TCR, which is critical for anti-tumor efficacy of TCR-Ts, could be isolated from T cells stimulated and activated by tumor-specific antigens. Some studies reported that neoantigens derived from somatic mutations could activate and enrich tumor-reactive T cells, which could mediate objective clinical responses [4–6]. However, in general, few neoantigens per patient could induce immune response in epithelial cancer [7] and additionally recent study reported that many tumor-specific antigens were derived from noncoding region [8], which suggested urgent need to find more tumor-reactive antigens, especially for cancers with low mutation burden. Autologous tumor cells (ATCs) expressing various tumor antigens could be unbiased stimulators in activating and enriching tumor-reactive T cells [9–11].

CD137 is a T cell activation marker and thus upregulation of CD137 expression on activated T cells could be used to identify and isolate tumor-reactive T cells [12, 13]. In this study, we attempted to use CD137 upregulation on tumor infiltrating lymphocytes (TILs) in vitro stimulated with autologous tumor cells to identify tumor-reactive T cells and subsequently isolate their TCRs which were then introduced into PBLs to generate tumor-reactive TCR-Ts. The specific recognition and killing capacity of TCR-Ts against autologous tumor cells in vivo and in vitro were observed and evaluated.

This strategy provides the means to generate tumor-reactive TCR-Ts for a truly tumor-specific ESCC treatment, which might also be applied for treatment of other cancers.

Methods

Patient samples

Tumor sample from a 63-year-old woman with metastasis ESCC from Peking University Cancer Hospital was

obtained in our preclinical research with informed consent. The tumor sample was collected in tubes containing sterile saline solution and resected into several fragments for a) TIL culture; b) generation of patient-derived xenograft (PDX) model. This study was approved by the Institutional Review Board of the Peking University School of Oncology, China.

Cell lines and monoclonal antibodies

HEK 293-FT (Life Technologies), a packaging cell line used to produce high-titer lentivirus supernatants, were cultured in complete Dulbecco's Modified Eagle Medium (DMEM, Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA) containing 0.1 mM MEM Non-Essential Amino Acids, 1 mM sodium pyruvate and 2 mM Glutamax (Life Technologies, USA) at 37 °C with 5% CO₂.

Flow cytometry staining antibodies were shown as below: CD3-BUV395 (Clone: UCHT1), CD4-PE-CF594 (Clone: RPA-T4), CD8-PE-Cy7 (Clone: RPA-T8), PD-1-BUV737 (Clone: EH12.1), CCR7-PE (Clone: 150503), CD45RA-APC (Clone: HI100), CD137-APC (Clone: 4B4-1), CD107A-AF647 (Clone: H4A3), CD107b-AF647 (Clone: H4B3), Fixable Viability Stain 780 (FVS780). All antibodies were from BD Biosciences, except for anti-mouse TCR- β constant region (clone H5-597, eBioscience, USA). The blocking antibody against HLA class I were from eBioscience (clone: W6/32).

HLA typing for the patient and donors

DNA of autologous tumor cells or the patient or donors' peripheral blood were extracted with DNeasy Blood & Tissue Kit (QIAGEN, Germany) according to the manufacturer's protocol. Genotyping of HLA alleles was performed using high-resolution, high-throughput HLA genotyping with deep sequencing (BGI Diagnosis, Shenzhen, China). The HLA types of the patient and donors were outlined in Additional file 2: Table S1.

Generation of TILs, PDX models and autologous tumor cells

TILs were generated as previous described [14, 15] with slightly modification. Briefly, tumor sample was minced into approximately 1–2 mm fragments and each fragment was placed into a well of a 24-well plate comprised of T cell media and 50 ng/mL OKT3 antibody (ACRO, USA). T cell media consisted of X-VIVO 15 (Lonza,

USA); Glutamax (Life Technologies, USA); IL-2 (50 U/mL, Perprotech, USA), IL-7 (10 ng/mL, Perprotech, USA); IL-15(10 ng/mL, Perprotech, USA). T cells were incubated at 37 °C with 5% CO₂, and passaged to maintain a density of 1 × 10⁶ cells/mL until there were enough TILs used for screening of tumor-specific T cells.

PDX model was established by implanting tumor fragments mixed with matrigel subcutaneously into immunodeficient NOD-SCID mice to generate PDX model. ESCC PDX models could be promising for individual therapy, since we have verified that the molecular characteristics of ESCC PDXs were in accordance with primary patient tumors in our previous study [16].

Autologous tumor cells were generated from tumor specimens based on successfully established PDX model [17]. Dissected tumor samples were dissociated into single-cell suspension, using the human Tumor Dissociation Kit (Miltenyi Biotech, Germany) with gentleMACS Octo Dissociator with Heaters (Miltenyi Biotech, Germany) according to the manufacturer's instructions. Single-cell suspensions were harvested, washed with 1 × phosphate-buffered saline (PBS), and then resuspended in 6-well plate with complete media (DMEM, 20% FBS, 2 mM Glutamax) at 37 °C with 5% CO₂.

TILs phenotypic characterization by flow cytometry

Single-cell pellets of TILs were stained with CD3-BUV395, CD4-PE-CF594, CD8-PE-Cy7, CCR7-PE, CD45RA-APC, PD-1-BUV737 antibody cocktails. Cells were washed with PBS prior to acquisition on BD FACS Aria III flow cytometer. Data files were analyzed using FlowJo vX software (FlowJo, Tree Star), gated on single cells. Dead cells and debris were excluded by staining with Fixable Viability Stain 780 (FVS780). Phenotypes of T cells were gated on total CD3⁺ T cells.

Initial screening of TILs for recognition of autologous tumor cells

Autologous tumor cells were pretreated with complete media containing DAC cocktails (DAC (10 μM, Sigma Aldrich, USA), IFNγ (100 U/mL, ACRO, USA) and TNF-α(10 ng/mL, ACRO,USA) for 48 h, which restored cell surface expression of HLA molecules through enhancing the mRNA expression of HLA-related molecular including TAP or LMP genes or inhibiting DNA methylation [18–20]. Both IFN-γ enzyme-linked immunospot (ELISPOT) and enzyme-linked immunosorbent assays (ELISA) were used to screen tumor-reactive TILs cocultured with pretreated ATCs.

IFN-γ ELISPOT assay

Human IFN-γ ELISPOT Kit (with precoated plates, Abcam, USA) was performed as the protocol's procedure. Briefly, 2 × 10⁴ T cells, rested in cytokines-free media

overnight, and 1 × 10⁴ PBS-washed autologous tumor cells were incubated together for approximately 20 h in the absence of exogenous cytokines at 37 °C with 5% CO₂. The number of colored spots was determined by ImmunoSpot plate reader and associated software (Cellular Technologies, USA).

IFN-γ ELISA assay

1 × 10⁶ responder cells (T cells) and 1 × 10⁵ target cells (ATCs) were incubated together in a 96-well plate in the absence of exogenous cytokines for 18–24 h. Coculture supernatant was transferred into a new 96-well plate, and IFN-γ concentration was measured by using commercially available human IFN-γ ELISA kit (ExCell Bio, China) as manufacturer's protocols. In HLA blocking experiment, ATCs were pretreated with HLA-blocking antibody (clone W6/32, 50 μg/mL). Following a 3.5-h incubation, 5 × 10⁴ target cells (ATCs) and 1 × 10⁵ responder cells (T cells) were cocultured overnight for assessment of IFN-γ releasing level with the standard IFN-γ ELISA procedure [21].

Cytotoxic assay

CFSE-based cytotoxicity assay was performed as previously described [22, 23] with slightly alteration. Target cells were labeled with 5 μM CFSE (BD Biosciences) for 10 min and then cocultured with TCR-Ts at 37 °C for 4 h, at E: T ratio of 1:1 and 4:1. After the coculture, 1 μg/mL propidium iodide (PI, BD Biosciences) was added for assigning the ratio of cell death, and the samples were analyzed by flow cytometry.

Enrichment and isolation of tumor-reactive TILs after repeated stimulation with autologous tumor cells

For enrichment of tumor-reactive TILs, 2 × 10⁶ TIL-F1 and TIL-F4 were stimulated with 2 × 10⁵ autologous tumor cells pretreated with DAC cocktails in T-cell media for 1 week, respectively, after which they were stimulated with autologous tumor cells one more time. Moreover, both pre- and post-stimulated TILs were cocultured with 1 × 10⁵ autologous tumor cells (E: T = 5: 1) to evaluate their ability of specifically identifying and killing autologous tumor cells using flow cytometry. Data were analyzed using FlowJo vX software (TreeStar Inc) after gating on live cells (FVS780 negative). Meanwhile, CD8⁺CD137⁺ T cells of pre- and post-stimulated TIL-F1 were sorted into 96-well PCR plates by single-cell sorting (Additional file 1: Figure S3). And then 96-well PCR plates were immediately put into liquid nitrogen and conserved in minus 80°C prior to running single-cell RT-PCR.

T cell receptor sequencing and analysis

For single-cell PCR, all the primer sequences were listed in Additional file 2: Table S2 as previously described [24] except that the primers of TRBC were optimized, the final concentration of each V α and V β region primers was 5 μ M, and final concentration of TRAC and TRBC primers was 20 μ M. The single-cell RT-PCR reaction condition for first-step RT-PCR was as follows: 30 min at 50 °C for RT reaction; 95 °C for 15 min and 30 cycles of 94 °C for 30s, 52 °C for 30s, 72 °C for 1 min; 72 °C for 10 min. For the second cycle, 2 μ L of cDNA product was used as template for TCR α / β separately in total 20 μ L 2nd-PCR TRA/TRB mix (Additional file 2: Table S3), containing multiple internal primer sequences (INT) of V α /V β and one primer for C α /C β , with PrimeSTAR[®] HS DNA Polymerase (Takara Bio, Japan). The cycling program was 98 °C for 1 min; 98 °C for 10s, 52 °C for 10s, 72 °C for 45 s \times 43; 72 °C for 10 min. The second PCR products were analyzed with TRA sequencing primer for TCR α or TRB sequencing primer for TCR β (Additional file 2: Table S3). PCR products were purified and sequenced by Sanger sequencing method. The TCR sequences were analyzed using IMGT/V-Quest tool (<http://www.imgt.org/>).

Construction of lentivirus vectors and transduction of PBLs

TCR α / β chains were synthesized (GenScript) and cloned into the lentivirus vector. TCR was constructed in a β / α chain order and its constant regions were replaced by mouse counterparts modified with interchain disulfide bond and hydrophobic substitution as previously described, which not only was convenient for detection of TCR-T, but also improved TCR pairing and TCR/CD3 stability [17, 25]. However, since murine constant region of TCR-T could potentially be immunogenic in clinical application, human constant region could be essential for construction of TCR in order to improve the longevity of TCR-T persistence and enhance their therapeutic efficacy in patients.

Transduction of PBLs was conducted as previously delineated [17, 21, 26] with slightly modification. In brief, human peripheral blood mononuclear cells (PBMCs) were separated by centrifugation on a Ficoll-Paque Plus (GE Healthcare, USA) and then stimulated in T-cell media with 50 ng/ml OKT3 and 1 μ g/ml anti-CD28 for 2 days before transduction. TCR lentivirus were generated by cotransfection of 293-FT cells with lentivector and packaging plasmids (ratio of pLP1: pLP2:pVSV-G is 2:2:1) using PEI MAX 40000 (Polysciences Inc. USA) [27]. The lentiviral supernatants were harvested at 48 and 72 h after transfection and concentrated using optimized ultracentrifugation approaches with 20,000 g, 90 min at 4 °C [28]. Activated T cells were transduced by

concentrated lentivirus at the presence of 8 μ g/mL polybrene (Sigma-Aldrich, USA). The transduction efficiency was assessed by flow cytometry using mouse TCR- β chain constant region staining.

Treatment of PDX models by TCR-Ts

NOD/SCID mice were used to establish patient-derived xenograft approved by the Institutional Review Board of the Peking University School of Oncology, China. Tumor treatment was on days 5 and 12 following tumor inoculation and consisted of two intravenous injections of 4×10^6 T cells as well as a single intraperitoneal injection of 5 mg/kg DAC on day 5. Tumor size was determined by caliper measurement of perpendicular diameters of each tumor and was calculated using the following formula: tumor volume (mm^3) = [(length) \times (width) \times (width)]/2.

Statistics analysis


Statistical analysis was performed using GraphPad Prism 7.0 (GraphPad Software, CA) and SPSS software (version 24; IBM SPSS, Armonk, NY, USA). Statistical comparison was conducted with Student's t test, and two-way repeated measures ANOVA. All tests were two-sided and p value < 0.05 was considered statistically significant. All in vitro experiments were performed more than three independent experiments.

Results

Phenotype and functional screening of different TIL fragments

Tumor specimen was obtained from a 63-year-old woman with ESCC. Clinical characteristics and HLA types of the patient are outlined in Additional file 2: Table S1. In order to screen tumor-reactive TILs, we obtained four TIL fragments (TIL-F1 to TIL-F4) from different areas in one resected lesion.

To evaluate spatial heterogeneity of TILs, we measured the phenotypic characteristics of four TIL fragments derived from different anatomical sites of tumor sample by flow cytometry. The percentages of CD3⁺ T cells in all four TIL fragments were similar and approximately 99% (Additional file 1: Figure S1). However, percentages of CD4⁺ TILs hugely varied from 30.6 to 87.7%, and percentages of CD8⁺ TILs from 9.67 to 63.6%, suggesting significant difference in distribution of CD4⁺ and CD8⁺ TILs among different anatomical sites (Fig. 1a and b). The level of PD-1 expression hugely varied in four TIL fragments, with higher proportions in TIL-F1 and TIL-F2 (35.8 and 30.7%, respectively; Fig. 1c and d). The percent of effector-memory T cells (CCR7⁻CD45RA⁻) was highest in all four TIL fragments, followed by effector T cells (CCR7⁻CD45RA⁺), as showed in Fig. 1e and Additional file 1: Figure S2.



To screen tumor-reactive TILs, TILs (TIL-F1 to TIL-F4) were separately co-cultured with ATCs and we found TIL-F1 co-cultured with ATCs produced a significantly higher level of IFN- γ than TIL-F1 alone but this finding was not found in TIL-F2 to TIL-F4 by enzyme-linked immunospot (ELISPOT) assay and enzyme-linked immunosorbent (ELISA) assay (Fig. 1f and g). These data suggested that TIL fragments derived from different tumor sites were spatially heterogeneous and additionally TIL-F1 had potential anti-tumor activities.


Isolation of tumor-reactive TCRs from TIL-F1 based on CD137 expression by in vitro stimulation of ATCs and sorting

To further validate anti-tumor activity of TIL-F1 and isolate tumor-reactive TCRs, TIL-F1 was stimulated with ATCs for twice, and single CD8⁺ CD137⁺ TIL-F1 before and after stimulation (namely PRE and POST) were both sorted into 96-well plates and were amplified using single-cell PCR to obtain their TCRs, presented in Fig. 2. Therefore, the most dominant TCR of post-stimulated CD8⁺ CD137⁺ TIL-F1 could be most likely tumor-

reactive TCR, which was transduced into donor PBLs to generate tumor-reactive TCR-Ts. To exclude possibility of non-specific amplification of TIL-F1 stimulated with ATCs, TIL-F4 as a negative control was also stimulated with ATCs based on the same stimulation procedure as TIL-F1. The flow cytometry-based assays indicated that the percentage of tumor-reactive T cells in post-stimulated TIL-F1 was significantly higher than that in pre-stimulated TIL-F1 and yet percentages of tumor-reactive T cells in pre- and post-stimulated TIL-F4 were low and similar (Fig. 3).

Construction and functional validation of tumor-reactive TCR-Ts

We isolated approximately 100 CD8⁺ CD137⁺ T cells from pre- and post-stimulated TIL-F1 co-cultured with ATCs. 43 and 42 TCR α/β chain pairs were identified by single-cell TCR sequencing from pre- and post-stimulated CD8⁺ CD137⁺ T cells, respectively (Table 1 and Table 2). The percentages of the first, second and third ranked TCRs in pre-stimulated CD8⁺ CD137⁺



TIL-F1 were 58.54, 14.63, 9.76%, respectively (Table 1, Fig. 4a). After stimulation, the percentage of only the first ranked TCR (namely TCR1) in pre-stimulated TIL-F1 significantly increased (Table 2, Fig. 4b), which suggested that the first ranked TCR could be most likely tumor-reactive TCR.

To optimize expression of introduced TCR in T cells, TCR was constructed in a β/α chain order and constant regions was replaced by mouse counterparts modified with interchain disulfide bond and hydrophobic substitution as previously described (Fig. 4c) [17, 25]. The first ranked TCR was lentivirally transduced into PBLs to

generate TCR-Ts with transduction efficiency of more than 50% (Fig. 4d).

The ability of these TCR-Ts to specifically identify and mediate effector functions in response to autologous tumor cells in vitro was evaluated with cytokine production and T cell cytotoxicity assays. The TCR-Ts showed high levels of IFN- γ secretion and specific cytotoxicity to ATCs (Fig. 4e, f and Additional file 1: Figure S5). Besides, we found that TCR-Ts displayed significantly diminished levels of IFN- γ with HLA class I blocking antibodies, which indicated the recognition effect of TCR-Ts was mainly restricted by HLA class I presentation (Additional




Fig. 3 Enrichment of TIL-F1 and TIL-F4 by in vitro repetitive stimulation of ATCs. TIL-F1 and TIL-F4 were stimulated by autologous tumor cells (ATCs) for 1 week, respectively, after which they were stimulated with ATCs one more time. Flow cytometry analysis was used to evaluate specific recognition and cytotoxicity of both pre- and post-stimulated TILs against ATCs by staining cells with CD137 antibody (a), CD107 antibody (b) and PI antibody (c). Data are representative of more than three independent experiments

Table 1 TCR genes of CD8⁺CD137⁺T cells in pre-stimulated TIL-F1

ID	TRAV	TRAJ	CDR3 aa seq.	TRBV	TRBD	TRBJ	CDR3 aa seq.	CD8 ⁺ CD137 ⁺	
								Rank	Freq. (%)
1	TRAV4*01	TRAJ8*01	LVGDGKNTGFQKLV	TRBV7-9*03	TRBD2*01	TRBJ2-7*01	ASSLKPGEQY	1	58.54
2	TRAV1-2*01	TRAJ40*01	AVRAPLLPQEPTNT	TRBV7-9*03	TRBD2*01	TRBJ2-7*01	ASSLKPGEQY	2	14.63
3	TRAV1-2*01	TRAJ16*01	VPLDGQKLL	TRBV3-1*01	TRBD1*01	TRBJ2-5*01	ASSQESQTGPIGGTQY	3	9.76
4	TRAV13-1*02	TRAJ52*01	AASDNDAGGTSYGKLT	TRBV6-6*01	TRBD2*01	TRBJ1-2*01	ASSYNGSAGGYYGYT	4	4.88
5	TRAV8-6*02	TRAJ32*02	AVPWLQTSS	TRBV7-3*01	TRBD2*01	TRBJ2-1*01	ASSLGGNEQF	5	2.44
6	TRAV1-2*01	TRAJ15*01	AVRETGQAGTALI	TRBV28*01	TRBD1*01	TRBJ2-7*01	ASRLDRASSYEQY	6	2.44
7	TRAV21*01	TRAJ6*01	AAGIRRKLHTY	TRBV19*01	TRBD1*01	TRBJ1-1*01	ASSITGRTEAF	7	2.44
8	TRAV41*01	TRAJ45*01	AVSRGHDSGGGADGLT	TRBV6-5*01	TRBD1*01	TRBJ2-7*01	ASSYGDSYEQY	8	2.44
9	TRAV19*01	TRAJ53*01	ALSLNSGGSNYKLT	TRBV7-9*03	TRBD2*01	TRBJ2-1*01	ASSPVLNEQF	9	2.44

TCR T-cell receptor, CDR3 Complementarity-determining region, V Variable, D Diversity, J Joining, TRAV T-cell receptor Va, TRBV T-cell receptor Vb *subtypes of TCR genes

Table 2 TCR genes of CD8⁺CD137⁺T cells in post-stimulated TIL-F1

ID	TRAV	TRAJ	CDR3 aa seq.	TRBV	TRBD	TRBJ	CDR3 aa seq.	CD8 ⁺ CD137 ⁺	
								Rank	Freq. (%)
1	TRAV4*01	TRAJ8*01	LVGDGKNTGFQKLV	TRBV7-9*03	TRBD2*01	TRBJ2-7*01	ASSLKPGEQY	1	72.09
2	TRAV1-2*01	TRAJ40*01	AVRAPLLPQEPTNT	TRBV7-9*03	TRBD2*01	TRBJ2-7*01	ASSLKPGEQY	2	11.63
10	TRAV13-1*02	TRAJ22*01	APLSGSARQLT	TRBV7-9*03	No Result	TRBJ2-2*01	ASSLVPGEQY	3	9.30
11	TRAV8-4*05	TRAJ40*01	WPPTTSGTYKYI	TRBV9*01	TRBD2*02	TRBJ2-3*01	ASSTGGGKTDQY	4	4.65
12	TRAV39*01	TRAJ42*01	AVEDWGGSQGNLI	TRBV19*01	TRBD2*01	TRBJ2-1*01	ASSPASVQGEQF	5	2.33

TCR T-cell receptor, CDR3 Complementarity-determining region, V Variable, D Diversity, J Joining, TRAV T-cell receptor Va, TRBV T-cell receptor Vβ *subtypes of TCR genes

file 1: Figure S4). To further explore the potential cytotoxicity of TCR-Ts to mediate regression of tumor in vivo, a single intravenous injection of TCR-Ts with intraperitoneal DAC was administered into patient-derived xenograft (PDX) models [18, 19]. Of note, administration of TCR-Ts induced a statistically significant regression of tumors than untreated group, untransduced T cells treated group or DAC treated group (Fig. 4g, $p < 0.001$). These findings revealed that tumor-reactive TCR-Ts could exert an anti-tumor activity against ESCC in vivo and in vitro.

Discussion

Although the adoptive transfer of TILs could mediate regression of metastatic melanoma, most patients with metastatic epithelial cancers did not respond to this therapy [29]. One potential contributing factor could be that TILs used for treatment not only underwent extensive in vitro expansion, but also were usually highly differentiated and exhausted cells with impaired efficacy and limited proliferative potential [30]. Therefore, TCRs isolated from exhausted tumor-specific TILs are introduced into PBLs without impaired immune function to generate tumor-reactive TCR-Ts, which could show stronger anti-tumor response compared with TILs.

In this study, we found phenotype and effect function of TIL fragments derived from different tumor sites were spatially heterogeneous. Of four TIL fragments, only TIL-F1 could specifically identify and kill autologous tumor cells. Therefore, we enriched tumor-reactive T cells from TIL-F1 by in vitro repeated stimulation of autologous tumor cells. Subsequently, we isolated tumor-specific CD8⁺ CD137⁺ T cells from pre- and post-stimulated TIL-F1 co-cultured with tumor cells and identified their most dominant TCRs by single-cell TCR sequencing. Then this TCR was introduced into donor PBLs to generate tumor-reactive TCR-Ts, which specifically identified and killed autologous tumor cells in vivo and in vitro.

The percentages of effector-memory and effect T cells were highest in all four TIL fragments and moreover all four TIL fragments had different expression levels of PD1, which indicated different levels of impairment on proliferation ability and functional activity of all four

TIL fragments. Therefore, although TIL-F1 specifically identified autologous tumor cells, their effect function could be impaired [31]. Hence, TCR isolated from tumor-reactive and exhausted TILs was introduced into PBL without impaired immune function to generate tumor-reactive TCR-Ts, which could show stronger anti-tumor efficacy compared with matched TILs.

Recently, most studies demonstrated that TILs were cultured with autologous dendritic cells pulsed with neoantigens to enrich tumor-reactive TILs and isolate their TCRs, but only less than 1% of all somatic mutations could induce T-cell immune response in epithelial cancers [7]. Moreover, this approach was challenged by a recent study reporting that ~90% of tumor specific antigens were derived from noncoding regions instead of coding regions [8]. In addition, except for neoantigens, there could be many other tumor-specific antigens, such as phosphoprotein, glycoproteins, and glycolipids [32]. Thus, we speculated that autologous tumor cells could be an important source of tumor antigens and greatly expand tumor-specific T cells. In fact, it was reported that TILs could specifically identify and kill autologous tumor cells [9–11], and moreover our study demonstrated that TIL-F1 cultured with autologous tumor cells was activated and expanded.

CD137 is expressed on T cells recently activated by TCRs engagement, and expression of CD137 on T cells was used to identify and isolate tumor-specific T cells from PBLs and TILs [12, 13]. Therefore, in the study we used CD137 up-regulation after ATCs-stimulation to enrich tumor-reactive T cells and isolated their most dominant TCR. And then we found that PBLs modified by the most dominant TCR could identify and kill autologous tumor cells in vivo and in vitro. These findings indicated that autologous tumor cells could be used to enrich tumor-reactive CD137⁺ T cells of which TCRs could be applied for construction of TCR-Ts for patients with ESCC.

Since our study only enrolled one patient, it is difficult to comprehensively evaluate efficacy and success rates of obtaining tumor-reactive TILs and corresponding TCR-T, and thus we planned to enroll more patients to validate efficacy of our approach in the future study. In




Fig. 4 Identification of tumor-specific TCRs and functional verification of corresponding TCR-Ts. TCRs distribution of CD8⁺ CD137⁺ T cells in pre- **(a)** and post-stimulated **(b)** TIL-F1 by single-cell RT-PCR analysis. TCRs sequences are listed with different colors in order from most to least frequent, named TCR1 to TCR12, respectively. **c** Sketch map of pCDH-EF1 α -TCR1 lentiviral vector. The construct employed the β - α chain order, added murine constant region, disulfide bond (presented as black dots), and a chain hydrophobic-substitutions (presented as red dot). Leader, leader sequences of TCR α and TCR β chains, respectively; EF1 α promoter, elongation factor 1 alpha promoter; F2A linker, Furin-P2A linker. **d** Transduction efficiencies were measured by staining cells with an anti-murine TCR- β chain constant region antibody. The results were representative of independent experiments done with more than three different donors. **e** Cytotoxicity capacity of TCR-Ts against ATCs. Line chart summarized the cytotoxicity by subtracting the ATCs spontaneous death at different E: T ratios. Data were representative of at least three independent experiments with more than three different donors. **f** IFN- γ ELISA measurement of TCR-Ts and TNC targeting ATCs. The results are representative of more than three independent experiments in more than three different donors (* $p < 0.05$, Student paired t test). **g** Antitumor activity of TCR-Ts against patient derived xenograft models. The tumor volume is plotted on the y axis. Time after tumor cell injection is plotted on the x axis. The mean values from each group are plotted. Error bars represent the SEM ($n = 5$ mice per group, *** $p < 0.001$, analyzed by two-way repeated measures ANOVA). The results are representative of 2 independent experiments. MOCK, none; TNC, two intravenous injections of untransduced T cells; DAC, a single intraperitoneal injection of DAC; TCR-T, two intravenous injections of TCR-Ts; DAC + TCR-T, two intravenous injections of TCR-Ts and a single intraperitoneal injection of DAC

addition, since our current approach is limited by low-throughput single-cell RT-PCR and Sanger sequencing method, in the future study, we attempted to screen multiple tumor-reactive TCRs from TILs stimulated with ATCs using high-throughput single-cell RNA sequencing method [33, 34].

Conclusion

We report a strategy based on stimulation with autologous tumor cells and single cell sorting of CD137⁺ T cells for induction of tumor-reactive T cells, isolation of TCRs and construction of TCR-Ts for ESCC, which is especially important for patients without prior knowledge of the specific epitopes and might be applied for other cancers.

Additional files

Additional file 1: Figure S1. Frequency of CD3⁺ T cells in all four TIL fragments. Gated on live CD3 positive population. **Figure S2.** Memory phenotypic characterizations of all four TIL fragments from ESCC patient. **Figure S3.** General view of location and number of cells sorted into 96-well PCR plate. **Figure S4.** HLA-I blocking experiment of TCR-T cells targeting autologous tumor cells by IFN γ -ELISA. **Figure S5.** IFN γ ELISA for TCR-T cells targeting ATCs pretreated with DAC cocktails or not. (DOCX 314 kb)

Additional file 2: Table S1. Clinical characteristics of the patient and donors. **Table S2.** Sequences of the primers used for single cell TCR α / β RT-PCR. **Table S3.** Contents of 2-step single-cell RT-PCR. (XLSX 20 kb)

Abbreviations

ACT: Adoptive cell therapy; ATCs: autologous tumor cells; CDR3: complementarity determining region; CFSE: carboxyfluorescein succinimidyl amino ester; ELISA: enzyme-linked immunosorbent assay; ELISPOT: enzyme-linked immunospot; ESCC: esophageal squamous cell cancer; HLA: human leukocyte antigen; IFN- γ : interferon γ ; PBL: peripheral blood lymphocytes; PD-1: programmed cell death protein-1; PI: propidium iodide; TCR: T cell receptor; TCR-Ts: T cell receptor-engineered T cells; TILs: tumor infiltrating lymphocytes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

We thank Dr. Hongchao Xiong at the Department of Thoracic Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) for his assistance of providing surgical samples and clinical characterizations of the patient. Thank Dr. Huirong Ding at the Department of Central Laboratory, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) for her assistance of flow cytometry experiments.

Authors' contributions

ZML, YK and CTZ designed the study, QT collected, analyzed, and interpreted data, QT and CTZ wrote the manuscript. WJY, YL, PH and DDF analyzed data and provided statistical interpretation. All authors read and approved the final manuscript.

Funding

This work was supported by Beijing Natural Science Foundation (Grant No 7171001 to ZL, Grant No 7182029 to CZ); Beijing Municipal Science & Technology Commission (Grant No Z171100001017136 to ZL); The Charity Project of the National Ministry of Health (Grant No 201202014 to YK); Natural Science Foundation of China [Grant No 81621063 to YK, Grant No 81972880 to ZL]. Beijing Hospitals Authority Youth Programme (Grant No QMS20191108 to CZ).

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of the Peking University School of Oncology, China. Patient from Peking University Cancer Hospital was obtained in our preclinical research with informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Beijing 100142, China. ²Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Beijing 100142, China. ³Key Laboratory of Fertility Preservation and Maintenance (Ministry of Education), Cancer Institute of the General Hospital, Ningxia Medical University, Yinchuan, Ningxia 750004, People's Republic of China. ⁴Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head and Neck Surgery, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Beijing 100142, China.

Received: 15 March 2019 Accepted: 14 August 2019

Published online: 28 August 2019

References

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394–424.
- Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. *CA Cancer J Clin.* 2016;66(4):271–89.
- Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. *Nature.* 2017; 545(7655):423–31.
- Veatch JR, Lee SM, Fitzgibbon M, Chow IT, Jesernig B, Schmitt T, Kong YY, Kargl J, Houghton AM, Thompson JA, et al. Tumor infiltrating BRAFV600E-specific CD4 T cells correlated with complete clinical response in melanoma. *J Clin Invest.* 2018.
- Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, et al. T-cell transfer therapy targeting mutant KRAS in Cancer. *N Engl J Med.* 2016;375(23):2255–62.
- Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF, et al. Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. *Cancer immunology research.* 2016;4(8):669–78.
- Tran E, Robbins PF, Rosenberg SA. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. *Nat Immunol.* 2017;18(3):255–62.
- Laumont CM, Vincent K, Hesnard L, Audemard E, Bonneil E, Laverdure JP, Gendron P, Courcelles M, Hardy MP, Cote C, et al. Noncoding regions are the main source of targetable tumor-specific antigens. *Sci Transl Med.* 2018; 10:470.
- Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. *J Immunol.* 1991;146(10):3674–81.
- Meng Q, Valentini D, Rao M, Moro CF, Paraschoudi G, Jager E, Dodoo E, Rangelova E, Del Chiaro M, Maeurer M. Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer. *Br J Cancer.* 2019;120(1):97–108.
- Owens GL, Price MJ, Cheadle EJ, Hawkins RE, Gilham DE, Edmondson RJ. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells. *Cancer Immunol Immunother.* 2018;67(10):1519–31.
- Wolf M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, Greenberg PD. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. *Blood.* 2007;110(1):201–10.
- Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, Harada M, Kiyotani K, Lengyel E, Fleming GF, et al. Induction of Neoantigen-specific cytotoxic T cells and construction of T-cell receptor-engineered T cells for ovarian Cancer. *Clin Cancer Res.* 2018.
- Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. *J Clin Oncol.* 2016;34(20):2389–97.
- Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. *Science.* 2014;344(6184):641–5.
- Zou J, Liu Y, Wang J, Liu Z, Lu Z, Chen Z, Li Z, Dong B, Huang W, Li Y, et al. Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization. *J Transl Med.* 2018;16(1):15.
- Jin BY, Campbell TE, Draper LM, Stevanovic S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. *JCI Insight.* 2018;3:8.
- Everson RG, Antonios JP, Lisiero DN, Soto H, Scharnweber R, Garrett MC, Yong WH, Li N, Li G, Kruse CA, et al. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. *Neuro-Oncology.* 2016;18(3):368–78.

19. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. *Int J Cancer*. 2001;94(2):243–51.
20. Seliger B, Harders C, Lohmann S, Momburg F, Urlinger S, Tampé R, Huber C. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. *Eur J Immunol*. 1998;28(1):122–33.
21. Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. *Nat Med*. 2018;24(6):724–30.
22. Ankri C, Shamalov K, Horovitz-Fried M, Mauer S, Cohen CJ. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity. *J Immunol*. 2013;191(8):4121–9.
23. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. *Blood*. 2004;103(7):2677–82.
24. Dash P, Wang GC, Thomas PG. Single-cell analysis of T-cell receptor alphabeta repertoire. *Methods Mol Biol*. 2015;1343:181–97.
25. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. *Cancer Res*. 2006;66(17):8878–86.
26. Yossef R, Tran E, Deniger DC, Gros A, Pasetto A, Parkhurst MR, Gartner JJ, Prickett TD, Cafri G, Robbins PF, et al. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. *JCI Insight*. 2018;3:19.
27. Longo PA, Kavran JM, Kim MS, Leahy DJ. Transient mammalian cell transfection with polyethylenimine (PEI). *Methods Enzymol*. 2013;529:227–40.
28. Cribbs AP, Kennedy A, Gregory B, Brennan FM. Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells. *BMC Biotechnol*. 2013;13:98.
29. Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MAJ, Hirt C, Mezzadra R, Slagter M, Dijkstra K, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. *Nat Med*. 2019;25(1):89–94.
30. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumor T cell. *Nat Rev Cancer*. 2012;12(10):671–84.
31. Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. *Trends Immunol*. 2015;36(4):265–76.
32. Cobbold M, De La Pena H, Norris A, Polefrone JM, Qian J, English AM, Cummings KL, Penny S, Turner JE, Cottine J, et al. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. *Science translational medicine*. 2013;5(203):203ra125.
33. De Simone M, Rossetti G, Pagani M. Single cell T cell receptor sequencing: techniques and future challenges. *Front Immunol*. 2018;9:1638.
34. Ziegenhain C, Vieth B, Parekh S, Reinius B, Guillaumet-Adkins A, Smets M, Leonhardt H, Heyn H, Hellmann I, Enard W. Comparative Analysis of Single-Cell RNA Sequencing Methods. *Molecular cell*. 2017;65(4):631–643.e634.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

